In addition to the overall preferences for targeting prostate cancer‐related proteins, the screened drugs also targeted the epidermal growth factor receptor (EGFR) signaling pathway, protein degradation, DNA repair, and cell cycle‐related proteins. This evidence concerns the gene EGFR and prostate cancer.